Galectin Therapeutics
GALT
60 hedge funds and large institutions have $9.26M invested in Galectin Therapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 5 closing their positions.
7% more call options, than puts
Call options by funds: $185K | Put options by funds: $173K
0% more funds holding
Funds holding: 60 → 60 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0.69% less ownership
Funds ownership: 12.58% → 11.89% (-0.69%)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
75% less capital inflows, than outflows
Capital inflows: $206K | Capital outflows: $812K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
+$58.8K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$26.8K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$21.5K |
| 4 |
HF
HRT Financial
New York
|
+$21.3K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$16.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$251K |
| 2 |
KeyBank National Association
Cleveland,
Ohio
|
-$161K |
| 3 |
Millennium Management
New York
|
-$114K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$69.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$67.7K |
GALT Hedge Fund Activity: Q2 2022 in Review
60 of the 5,962 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2022, worth a combined $9.26M — down 23% from $12M a quarter earlier.
Fund positioning in GALT was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 11 added to existing stakes and 14 trimmed.
The largest buyer was William Blair & Company, opening a new position worth an estimated $58.8K. The largest seller was Renaissance Technologies, cutting an estimated $251K.
- 60 institutional investors held Galectin Therapeutics (GALT) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $9.26M of Galectin Therapeutics stock for Q2 2022, down 23% quarter-over-quarter.
- 5 funds opened new Galectin Therapeutics positions in Q2 2022 and 5 closed out, a net change of 0 holders.
- The largest Galectin Therapeutics buyer in Q2 2022 was William Blair & Company, an estimated $58.8K added.
- The largest Galectin Therapeutics seller in Q2 2022 was Renaissance Technologies, an estimated $251K sold.
Based on aggregated 13F filings for Q2 2022.